DUBLIN, April 28, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Hypertension Drugs Market 2016-2020" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) The global hypertension drugs market to decline at a CAGR of (0.93) % during the period 2016-2020 The report covers the present scenario and the growth prospects of the global hypertension drugs market for 201652020. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent hypertension and pulmonary arterial hypertension (PAH). The report also includes a discussion of the key vendors operating in this market.
The acceptability of hypertension drugs is expected to rise due to the growing awareness about hypertension and its treatment options. For instance, the National High Blood Pressure Education Program, coordinated by the National Heart, Lung, and Blood Institute of National Institutes of Health, is a cooperative effort among professionals, voluntary health agencies, and state health departments with a goal to cut down death and disability related to high BP through programs of professional, patient, and public education. According to the report, the prevalence of hypertension is high among the older population, with about 70% of high BP patients being above the age of 60. In 2013, the Pulmonary Hypertension Association in the UK reported 21% of the pulmonary hypertension patients to be in the age group of 60-69 years. The registry reported that in the UK and Ireland, 26% of the patients were in the age group 51-65 years while 23% were above 65 years. Around 11% of the global population is constituted by people aged 60 years and older, and by 2050, it is expected to rise to 22%. Thus, a steady increase in the hypertension prevalence population will drive the growth of the global hypertension drugs market. This leads to an increase in the costs associated with treatment, increasing the growth of the market. Further, the report states that patent expiries result in the loss of an exclusive market for a drug, leading to a rapid decline in the sales of the particular drug.
Key vendors - Actelion Ltd. - AstraZeneca plc - Boehringer Ingelheim GmbH - Daiichi Sankyo Company, Ltd. - Novartis AG - Sanofi SA Other prominent vendors
- Actelion Pharmaceuticals - Arena Pharmaceuticals - Asahi Kasei - Bayer HealthCare - Bellerophon Therapeutics - Bial - CJ HealthCare - Conatus Pharmaceuticals - Daiichi Sankyo - Deka Pharmaceuticals - Dong-A ST - Eiger BioPharmaceuticals - Forest Laboratories - Gilead Sciences - HanAll BioPharma - Hanmi Pharmaceutical - Johnson & Johnson - LG Life Sciences - Lung Biotechnology - Lupin Pharmaceuticals - Mast Therapeutics - Merck - Northern Therapeutics - Ono Pharmaceutical - Pfizer - Sun Pharmaceutical Industries - Symplmed Pharmaceuticals - Takeda Pharmaceuticals - United Therapeutics - Valeant Pharmaceuticals - XOMA - Yuhan
For more information visit http://www.researchandmarkets.com/research/kvhczt/global
Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Advertisement
Research and Markets has announced the addition of the "Global Hypertension Drugs Market 2016-2020" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) The global hypertension drugs market to decline at a CAGR of (0.93) % during the period 2016-2020 The report covers the present scenario and the growth prospects of the global hypertension drugs market for 201652020. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent hypertension and pulmonary arterial hypertension (PAH). The report also includes a discussion of the key vendors operating in this market.
Advertisement
The acceptability of hypertension drugs is expected to rise due to the growing awareness about hypertension and its treatment options. For instance, the National High Blood Pressure Education Program, coordinated by the National Heart, Lung, and Blood Institute of National Institutes of Health, is a cooperative effort among professionals, voluntary health agencies, and state health departments with a goal to cut down death and disability related to high BP through programs of professional, patient, and public education. According to the report, the prevalence of hypertension is high among the older population, with about 70% of high BP patients being above the age of 60. In 2013, the Pulmonary Hypertension Association in the UK reported 21% of the pulmonary hypertension patients to be in the age group of 60-69 years. The registry reported that in the UK and Ireland, 26% of the patients were in the age group 51-65 years while 23% were above 65 years. Around 11% of the global population is constituted by people aged 60 years and older, and by 2050, it is expected to rise to 22%. Thus, a steady increase in the hypertension prevalence population will drive the growth of the global hypertension drugs market. This leads to an increase in the costs associated with treatment, increasing the growth of the market. Further, the report states that patent expiries result in the loss of an exclusive market for a drug, leading to a rapid decline in the sales of the particular drug.
Key vendors - Actelion Ltd. - AstraZeneca plc - Boehringer Ingelheim GmbH - Daiichi Sankyo Company, Ltd. - Novartis AG - Sanofi SA Other prominent vendors
- Actelion Pharmaceuticals - Arena Pharmaceuticals - Asahi Kasei - Bayer HealthCare - Bellerophon Therapeutics - Bial - CJ HealthCare - Conatus Pharmaceuticals - Daiichi Sankyo - Deka Pharmaceuticals - Dong-A ST - Eiger BioPharmaceuticals - Forest Laboratories - Gilead Sciences - HanAll BioPharma - Hanmi Pharmaceutical - Johnson & Johnson - LG Life Sciences - Lung Biotechnology - Lupin Pharmaceuticals - Mast Therapeutics - Merck - Northern Therapeutics - Ono Pharmaceutical - Pfizer - Sun Pharmaceutical Industries - Symplmed Pharmaceuticals - Takeda Pharmaceuticals - United Therapeutics - Valeant Pharmaceuticals - XOMA - Yuhan
For more information visit http://www.researchandmarkets.com/research/kvhczt/global
Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
